RAPP Stock: Price, Earnings History and SEC Filings
Rapport Therapeutics, Inc. (RAPP) last traded at $25.05, up 3.47% on the latest session and down 25.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.19 against an analyst estimate of $-0.93, a miss of 28.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RAPP earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-1.19 | $-0.93 | -27.96% |
| Mar 2026 | May 7, 2026 | $-0.42 | $-0.56 | +25.00% |
| Dec 2025 | Mar 10, 2026 | $-0.72 | $-0.65 | -10.77% |
| Sep 2025 | Nov 6, 2025 | $-0.71 | $-0.77 | +7.79% |
RAPP beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How RAPP reacts to earnings
Across its last 8 earnings releases, RAPP moved 4.4% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | Before open | +0.57% |
| 2026-05-07 | Before open | +7.74% |
| 2026-03-10 | Before open | -2.98% |
| 2025-11-06 | Before open | -3.10% |
| 2025-08-07 | Before open | +5.48% |
| 2025-05-08 | Before open | +4.21% |
| 2025-03-11 | Before open | +8.34% |
| 2024-11-07 | Before open | +2.87% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RAPP financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$111M | -$88M | – | $-2.86 |
| 2024 | – | -$78M | -$67M | – | $-3.78 |
| 2023 | – | -$35M | -$29M | – | $-23.10 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RAPP
- 8-K · Oct 30, 2026Material agreement, Results of operations, New financial obligation
- 424B5 · Oct 30, 2026
- 424B5 · Oct 30, 2026
- 424B5 · Oct 27, 2026
- 424B5 · Oct 27, 2026
- 8-K · Oct 20, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote
- 10-Q · May 7, 2026
Insider filing activity
RAPP insiders filed 16 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RAPP news
- Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares FallOct 28, 2026 · finance.yahoo.com
- Rapport Therapeutics stock tumbles on $350M capital raiseOct 28, 2026 · finance.yahoo.com
- Rapport Therapeutics Sinks 22% on Discounted $350 Million Stock and Convertible Note RaiseOct 28, 2026 · tikr.com
- Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private PlacementOct 28, 2026 · finance.yahoo.com
- Rapport Therapeutics slides after pricing securities offeringsOct 28, 2026 · seekingalpha.com
- Rapport Therapeutics Launches $350 Mln Stock And Convertible Notes Offerings; Stock DownOct 28, 2026 · rttnews.com
- Rapport Therapeutics (RAPP) shares sink 20% after hoursOct 28, 2026 · msn.com
- Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private PlacementOct 27, 2026 · finance.yahoo.com
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.